Skip to main content

Shire (SHPG) - Get Free Report rose $2.50 to $183.50 after an early stage study showed encouraging results for the company's prospective treatment for hereditary angioedema, a condition that causes dangerous swelling of tissues. Results from a study assessing lanadelumab showed positive treatment effect with no serious adverse events. The data were published in the latest New England Journal of Medicine.

Bellicum Pharmaceuticals (BLCM) - Get Free Report rose 8.2% to $13.84. The Houston company Wednesday afternoon announced the presentation of updated results from its clinical study of of BPX-501 and rimiducid at the 2017 BMT Tandem Meetings. BPX-501 is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation.

Novocure (NVCR) - Get Free Report shares were up 6.3% to $7.60. The Saint Helier, Jersey-based company on Thursday reported a fourth-quarter net loss of $22.2 million compared with a net loss of $32.9 million in the year-ago period. Net revenues were $30.2 million, up 144% year-over-year.

Thinly traded Cyclacel (CYCC) - Get Free Report had dropped nearly 34% to $3.62 after its lead product candidate failed a late-stage leukemia study. In a study focusing on elderly patients newly diagnosed with acute myeloid leukemia, the subjects did not experience a meaningful increase in overall survival, although an improvement in complete remission rate was observed. The company said it plans parse the data more closely to identify patients most likely to benefit from treatment with the drug, sapacitabine.